XRTX
XORTX Therapeutics Inc
$
0.550
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.550
Open
0.550
VWAP
0.55
Vol
18.26K
Mkt Cap
2.91M
Low
0.550
Amount
10.04K
EV/EBITDA(TTM)
--
Total Shares
2.90M
EV
2.18M
EV/OCF(TTM)
--
P/S(TTM)
--
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2024Q4
--
--
0.000
-100%
--
--
-0.290
-38.3%
Estimates Revision
The market is revising No Change the revenue expectations for XORTX Therapeutics Inc. (XRTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -38.20%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-38.20%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for XORTX Therapeutics Inc (XRTX.O) is -0.73, compared to its 5-year average forward P/E of -2.17. For a more detailed relative valuation and DCF analysis to assess XORTX Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.17
Current PE
-0.73
Overvalued PE
-0.24
Undervalued PE
-4.10
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.25
Undervalued EV/EBITDA
-1.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.42
Current PS
0.57
Overvalued PS
1.52
Undervalued PS
-0.68
Financials
Annual
Quarterly
FY2025Q2
YoY :
-40.42%
-889.95K
Operating Profit
FY2025Q2
YoY :
-522.01%
-717.70K
Net Income after Tax
FY2025Q2
YoY :
-416.67%
-0.19
EPS - Diluted
FY2025Q2
YoY :
+9.35%
-815.34K
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
XRTX News & Events
Events Timeline
2025-10-21 (ET)
2025-10-21
08:15:11
Xortx Therapeutics sets price for 1.75 million shares at $0.63 in direct registered offering
2025-10-17 (ET)
2025-10-17
07:03:36
Xortx to Purchase Renal Anti-Fibrotic Therapeutic Program from Vectus for $3 Million
2025-09-03 (ET)
2025-09-03
07:06:20
Xortx Therapeutics Begins IND Preparation for XORLO in Gout Treatment Program
Sign Up For More Events
Sign Up For More Events
News
9.5
11-03BenzingaLucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading
7.0
10-21SeekingAlphaXORTX Therapeutics Secures 180-Day Extension from Nasdaq to Meet $1.00 Bid Price Requirement
7.0
10-20NewsfilterXORTX Receives Nasdaq Notification Concerning Minimum Bid Price Shortfall
Sign Up For More News
People Also Watch
FAQ
What is XORTX Therapeutics Inc (XRTX) stock price today?
The current price of XRTX is 0.55 USD — it has decreased -1.61 % in the last trading day.
What is XORTX Therapeutics Inc (XRTX)'s business?
What is the price predicton of XRTX Stock?
What is XORTX Therapeutics Inc (XRTX)'s revenue for the last quarter?
What is XORTX Therapeutics Inc (XRTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for XORTX Therapeutics Inc (XRTX)'s fundamentals?
How many employees does XORTX Therapeutics Inc (XRTX). have?